carbogen has been researched along with Carcinoma in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (62.50) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bussink, J; Folkes, LK; Kaanders, JH; Stratford, MR; van der Kogel, AJ | 1 |
| Bussink, J; Kaanders, JH; van der Kogel, AJ | 1 |
| Bussink, J; Heerschap, A; Kaanders, JH; Lok, J; Punt, CJ; van der Kogel, AJ; van Laarhoven, HW; Verhagen, I | 1 |
| Cladd, H; Goodchild, K; Hoskin, PJ; Phillips, H; Powell, ME; Rojas, A; Saunders, MI; Stratford, MR | 1 |
| Bernier, J; Bieri, S; Bolla, M; Denekamp, J; Dennis, MF; Hagen, F; Kocagöncü, O; Rojas, A; Stratford, MR | 1 |
| Kaanders, JH; Liefers, J; Marres, HA; Pop, LA; van Daal, WA; van den Hoogen, FJ; van der Kogel, AJ | 1 |
| Brauers, G; Chaplin, DJ; Collingridge, DR; Edwards, B; Hill, SA; Honess, DJ; Powell, NA | 1 |
| Dische, S; Hong, A; Michael, BD; Rojas, A; Rugg, T | 1 |
1 review(s) available for carbogen and Carcinoma
| Article | Year |
|---|---|
ARCON: a novel biology-based approach in radiotherapy.
Topics: Animals; Carbon Dioxide; Carcinoma; Cell Cycle; Cell Hypoxia; Clinical Trials as Topic; Dose Fractionation, Radiation; Head and Neck Neoplasms; Humans; Mammary Neoplasms, Animal; Mice; Niacinamide; Oxygen; Patient Selection; Radiation-Sensitizing Agents; Radiotherapy; Urinary Bladder Neoplasms | 2002 |
3 trial(s) available for carbogen and Carcinoma
| Article | Year |
|---|---|
Carbogen and nicotinamide in the treatment of bladder cancer with radical radiotherapy.
Topics: Aged; Carbon Dioxide; Carcinoma; Chemotherapy, Adjuvant; Cohort Studies; Female; Humans; Male; Middle Aged; Niacinamide; Oxygen; Radiation-Sensitizing Agents; Radiotherapy, Adjuvant; Treatment Outcome; Urinary Bladder Neoplasms; Urination | 1997 |
Pharmacokinetics of nicotinamide in cancer patients treated with accelerated radiotherapy: the experience of the Co-operative Group of Radiotherapy of the European Organization for Research and Treatment of Cancer.
Topics: Administration, Oral; Area Under Curve; Carbon Dioxide; Carcinoma; Carcinoma, Non-Small-Cell Lung; Cell Hypoxia; Dose Fractionation, Radiation; Follow-Up Studies; Half-Life; Head and Neck Neoplasms; Humans; Lung Neoplasms; Nausea; Niacinamide; Oxygen; Pyridones; Radiation-Sensitizing Agents; Tablets; Time Factors; Treatment Outcome; Vomiting | 1998 |
Carbogen breathing: a system for use in man.
Topics: Administration, Inhalation; Adult; Aged; Bronchial Neoplasms; Carbon Dioxide; Carcinoma; Female; Humans; Leg; Male; Melanoma; Middle Aged; Oxygen; Pilot Projects; Radiation-Sensitizing Agents; Radiotherapy Dosage; Radiotherapy, High-Energy; Skin Neoplasms; Time Factors; X-Rays | 1992 |
4 other study(ies) available for carbogen and Carcinoma
| Article | Year |
|---|---|
Pharmacology and toxicity of nicotinamide combined with domperidone during fractionated radiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Carbon Dioxide; Carcinoma; Domperidone; Dose Fractionation, Radiation; Female; Humans; Male; Middle Aged; Nausea; Niacinamide; Oropharyngeal Neoplasms; Oxygen; Radiation-Sensitizing Agents; Vomiting | 2002 |
Modulation of hypoxia in murine liver metastases of colon carcinoma by nicotinamide and carbogen.
Topics: Animals; Carbon Dioxide; Carcinoma; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Drug Combinations; Female; Liver Neoplasms; Mice; Mice, Inbred BALB C; Niacinamide; Oxygen | 2005 |
Accelerated radiotherapy with carbogen and nicotinamide (ARCON) for laryngeal cancer.
Topics: Actuarial Analysis; Administration, Inhalation; Administration, Oral; Adult; Aged; Aged, 80 and over; Carbon Dioxide; Carcinoma; Cell Division; Cell Hypoxia; Dose Fractionation, Radiation; Feasibility Studies; Female; Follow-Up Studies; Humans; Laryngeal Neoplasms; Laryngectomy; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Niacinamide; Oxygen; Prospective Studies; Radiation-Sensitizing Agents; Radiotherapy Dosage; Salvage Therapy; Survival Rate | 1998 |
Preclinical evaluation of the novel hypoxic marker 99mTc-HL91 (Prognox) in murine and xenograft systems in vivo.
Topics: Adenocarcinoma; Animals; Carbon Dioxide; Carcinoma; Cell Hypoxia; Colonic Neoplasms; Contrast Media; Humans; Lung Neoplasms; Mice; Mice, Inbred CBA; Mice, SCID; Niacinamide; Organotechnetium Compounds; Oximes; Oxygen; Radiopharmaceuticals; Sarcoma | 1998 |